Implications of trial results: The potentially misleading notions of number needed to treat and average duration of life gained

Lancet

Volumn 356, Issue 9243, 2000, Pages 1757-1759

  Lubsen, Jacobus ^a,b   Hoes, Arno ^c   Grobbee, Diederick ^c  

^a SOCAR RESEARCH SA   (Switzerland)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ENALAPRIL; FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; CALCULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DECISION MAKING; FOLLOW UP; HUMAN; LIFE EXPECTANCY; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RISK BENEFIT ANALYSIS; SAMPLING;

EID: 0034684428     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03215-3     Document Type: Note

References (9)

1. The number needed to treat: A clinically useful measure of treatment effect
2. Shifts in mortality curves: Saving or extending lives?
3. An assessment of clinically useful measures of the consequences of treatment
4. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction: ISIS-2
5. Calculating the number needed to treat for trials where the outcome is time to an event
6. Effect of enalapril on survival inpatients with reduced left ventricular ejection fractions and congestive heart failure
7. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
8. Number-needed-to-treat and placebo-controlled trials
9. Numbers needed to treat derived from meta-anaiyses - Sometimes informative, usually misleading